Cortelli P, Dahlöf C, Bouchard J, Heywood J, Jansen J P, Pham S, Hirsch J, Adams J, Miller D W
Clinica Neurologica, Università di Bologna, Italy.
Pharmacoeconomics. 1997;11 Suppl 1:35-42. doi: 10.2165/00019053-199700111-00006.
This report presents the workplace productivity and non-workplace activity results of a multinational study of the effects of subcutaneous sumatriptan 6 mg in the acute treatment of migraine compared with patient's customary therapy. Patients diagnosed with migraine treated their symptoms for 24 weeks with subcutaneous sumatriptan after a 12-week period of treating symptoms with their customary (non-sumatriptan) therapy. Patients used diary cards to record information concerning the effects of migraine on workplace productivity and non-workplace activity time. The average workplace productivity time lost was 23.4 hours per patient during 12 weeks of customary therapy, compared with 7.2 and 5.8 hours per patient during the first and second 12-week periods of sumatriptan therapy, respectively. An average of 9.3 hours of non-workplace activity time was lost per patient during the customary therapy phase, compared with 3.2 and 2.8 hours during the first and second 12-week periods of sumatriptan therapy, respectively. Treatment of migraine with subcutaneous sumatriptan compared with customary therapy was associated with an average gain per patient of approximately 16 hours of workplace productivity time and 6 hours of non-workplace activity time, over a 3-month period.
本报告展示了一项多国研究的工作场所生产力和非工作场所活动结果，该研究对比了皮下注射6毫克舒马曲坦与患者常规疗法在偏头痛急性治疗中的效果。被诊断为偏头痛的患者在使用其常规（非舒马曲坦）疗法治疗症状12周后，再用皮下注射舒马曲坦治疗症状24周。患者使用日记卡记录有关偏头痛对工作场所生产力和非工作场所活动时间影响的信息。在常规疗法的12周期间，每位患者平均损失的工作场所生产力时间为23.4小时，而在舒马曲坦治疗的第一个和第二个12周期间，每位患者分别损失7.2小时和5.8小时。在常规治疗阶段，每位患者平均损失9.3小时的非工作场所活动时间，而在舒马曲坦治疗的第一个和第二个12周期间，分别损失3.2小时和2.8小时。与常规疗法相比，皮下注射舒马曲坦治疗偏头痛在3个月的时间里，每位患者平均可增加约16小时的工作场所生产力时间和6小时的非工作场所活动时间。
